Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02187198 · ClinicalTrials.gov registry record · Phase 3

Buprenorphine Treatment for Opioid Dependence

A Phase 3 study of Opioid Dependence, sponsored by Yale University.

Completed
Registry status
Phase 3
Development phase
9
Enrollment target
1
Study location

NCT02187198 is a Phase 3 study of Opioid Dependence that has completed, run by Yale University. The registered enrollment target is 9 participants, below the 158-participant average among 29 other Opioid Dependence trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02187198, a Phase 3 study of Opioid Dependence, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 3
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

Buprenorphine/naloxone (BUP/NLX) treatment is effective for the treatment of prescription opioid dependence, previous studies have not determined the optimum dose of BUP/NLX for this patient population. The goal of this study is to determine if there are differences in clinical efficacy of BUP/NLX tablet in low dose range (less than or equal to 8/2mg) vs. high dose range (greater than or equal to 16, range 16-24mg). The main outcomes of interest will be treatment retention, use of opioids, and the use of other drugs of abuse.

Conditions Studied

Opioid Dependence

Interventions

  • DRUG Buprenorphine

Study Locations (1)

Connecticut

  • VA Connecticut Healthcare System - West Haven Campus - West Haven

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2015-03
Est. Completion 2023-01-01
Phase Phase 3

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02187198

The ClinicalTrials.gov registry entry for NCT02187198 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 158-participant average among 29 other Opioid Dependence trials with a reported enrollment target (94% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Dependence appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.

NCT02187198 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT02187198 about?

NCT02187198 is a clinical study titled "Buprenorphine Treatment for Opioid Dependence". Buprenorphine/naloxone (BUP/NLX) treatment is effective for the treatment of prescription opioid dependence, previous studies have not determined the optimum dose of BUP/NLX for this patient population. The goal of this study is to determine if there are differences in clinical efficacy of BUP/NLX t...

What is the current status of trial NCT02187198?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2015-03. Estimated completion is 2023-01-01.

What conditions does trial NCT02187198 study?

This clinical trial studies the following conditions: Opioid Dependence.

What interventions are being tested in trial NCT02187198?

The interventions under investigation include: Buprenorphine (DRUG).

Who is sponsoring clinical trial NCT02187198?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02187198 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Opioid Dependence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Opioid Dependence

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.